Staff inspect experimental materials modified through plant gene-editing technology in a smart full-sunlight greenhouse at Shunfeng Biotechnology. Photo: Jinan News China has explicitly designated gene-editing as a critical core agricultural technology for the first time in its national planning, signaling a major state-backed push to advance high-tech seed breeding and bolster food security. The ...
Staff inspect experimental materials modified through plant gene-editing technology in a smart full-sunlight greenhouse at Shunfeng Biotechnology. Photo: Jinan News China has explicitly designated gene-editing as a critical core agricultural technology for the first time in its national planning, signaling a major state-backed push to advance high-tech seed breeding and bolster food security. The State Council recently released its 15th Five-Year Plan for Accelerating Agricultural and Rural Modernization. The plan outlines key technological breakthroughs to be pursued under the banner of “agricultural new quality productive forces.” It calls for developing new gene-editing tools and accelerating innovations in multi-target, high-efficiency gene editing and precise single-base editing.
Tasos Katopodis/Getty Images Entertainment Bitcoin advocate and Strategy ( MSTR ) executive chairman, Michael Saylor, attributed Bitcoin's ( BTC-USD ) recent selloff to a shift of investor capital into AI rather than any deterioration in the cryptocurrency's long-term fundamentals. “Capital markets are funding the AI buildout at historic scale: ~$400B over 6 months,” Saylor wrote in his l atest po...
Tasos Katopodis/Getty Images Entertainment Bitcoin advocate and Strategy ( MSTR ) executive chairman, Michael Saylor, attributed Bitcoin's ( BTC-USD ) recent selloff to a shift of investor capital into AI rather than any deterioration in the cryptocurrency's long-term fundamentals. “Capital markets are funding the AI buildout at historic scale: ~$400B over 6 months,” Saylor wrote in his l atest post on X.com. “Bitcoin ETFs have seen ~$4B of outflows since May 14, pressuring BTC. This is a capital rotation, not a Bitcoin impairment.” He added that “volatility creates opportunity.” However, Saylor's comments came as Strategy ( MSTR ) disclosed its first Bitcoin sale in years. In a June 1 filing , the company said it sold 32 BTC between May 26 and May 31 at an average price of $77,135 per coin, generating about $2.5M in net proceeds to help fund dividend payments on its preferred shares. While some market participants viewed the move as a sign of weakness, Saylor maintained that the company's long-term Bitcoin strategy remains unchanged. Strategy ( MSTR ) continues to hold ~843,706 Bitcoin, making it the largest corporate holder of the cryptocurrency. To note, Bitcoin's price has dropped over 14% in the past seven days and nearly 23% over the past month amid continued selling pressure. More on Grayscale Bitcoin Mini Trust ETF, Bitcoin USD, etc. The Everything Bubble (Except Bitcoin) I Won't Quit On Strategy Bitcoin Potential Near-Term Bullish Reversal Emerging From The Sub-$70K Plunge Bitcoin treasury firms shed $62B in market value as crypto rout deepens $10.8B paper loss raises question—Did Strategy misjudge the Bitcoin cycle?
The S & P 500 is on track for its longest weekly win streak since 1985, as investors count down to May's nonfarm payroll report. It comes as Asia's red-hot AI boom looks to have soured, with South Korea's Kospi and Japan's Nikkei ending the week in the red. Here are three investment strategies we heard in CNBC's Singapore and London studios to help navigate the noise. Risk reward entry point Timot...
The S & P 500 is on track for its longest weekly win streak since 1985, as investors count down to May's nonfarm payroll report. It comes as Asia's red-hot AI boom looks to have soured, with South Korea's Kospi and Japan's Nikkei ending the week in the red. Here are three investment strategies we heard in CNBC's Singapore and London studios to help navigate the noise. Risk reward entry point Timothy Moe, Goldman Sachs chief APAC equity strategist, continues to believe memory stocks have room to run, telling CNBC that equities in the space "are the stars of the show." However, he also highlights the defense sector, where a recent sell-off Moe describes as an understandable "technical correction" that presents an opportunity for investors. "Fundamentals have improved. All the stocks that we look at have increased their orders, valuations are attractive, and so we think that there's an interesting risk-reward entry point here for that part of the market". 'No risk' to hyperscaler capex Jean-Louis Nakamura, head of conviction equities at Vontobel, sees a continuation of the AI boom, telling CNBC that there is "no risk" hyperscalers will revise their capex plans lower within the next 12 to 18 months. He believes the trends in price and earnings will continue for chip manufacturers and memory producers. Nakamura also revealed that Vontobel has selectively strengthened its positions within a select few Chinese internet platforms, which have been "over-punished" in recent months "We think they are in a relatively good position to ultimately monetize AI on top of a very large pool of individual private data", he said. Mid-cap play Roger Lee, head of equity strategy at Cavendish, says mid-cap stocks could offer value if oil prices continue to fall, as lower energy prices ease pressure on inflation and interest rate expectations. Lee argues that equity markets, excluding U.S. technology, are heavily influenced by the price of oil because of its impact on inflation expectations...
Revolution Medicines (NASDAQ: RVMD) looks unstoppable. The clinical-stage biotech company has been riding the wave of impressive clinical progress, sending its stock price up nearly 100% this year alone and about 285% over the past 12 months, as of this writing. The market clearly has high hopes for Revolution Medicines, but can the company live up to the expectations? Let's consider the bull and ...
Revolution Medicines (NASDAQ: RVMD) looks unstoppable. The clinical-stage biotech company has been riding the wave of impressive clinical progress, sending its stock price up nearly 100% this year alone and about 285% over the past 12 months, as of this writing. The market clearly has high hopes for Revolution Medicines, but can the company live up to the expectations? Let's consider the bull and the bear case for this drugmaker. Revolution Medicines focuses on developing drugs for RAS-addicted cancers . RAS is a family of proteins that act as molecular switches in controlling cell growth. They can be turned "on" or "off." In RAS-addicted cancers, mutations keep RAS stuck in the "on" position, and the cancer cells become dependent on that constant growth signal to proliferate. Revolution Medicines is targeting this category because it is a vast, high-unmet-need space. The company's targets include pancreatic cancer, colorectal cancer -- the second leading cause of cancer death in the world -- as well as the first on that list, lung cancer. Image source: Getty Images. Continue reading
UBS CEO Warns Swiss Population Cap Is An 'Extreme' Measure A proposal headed for a June 14 vote in Switzerland made headlines for seeking to place a hard cap on the country's permanent resident population at 10 million through 2050. The vote is also being watched as a referendum on immigration pressure in Europe more broadly. UBS CEO Sergio Ermotti has caught the vapors over the idea , describing ...
UBS CEO Warns Swiss Population Cap Is An 'Extreme' Measure A proposal headed for a June 14 vote in Switzerland made headlines for seeking to place a hard cap on the country's permanent resident population at 10 million through 2050. The vote is also being watched as a referendum on immigration pressure in Europe more broadly. UBS CEO Sergio Ermotti has caught the vapors over the idea , describing it as an "extreme" measure that fails to address the country's underlying challenges. UBS CEO Sergio Ermotti (photo: Chiara Zocchetti ) " I do worry about these extreme initiatives ," Ermotti said, speaking from the Swiss Economic Forum in Interlaken on Thursday. "Switzerland has 30% of foreign-born people, almost like in Australia, twice as Germany. And that leads to certain frustration within society. But it's not a way to solve the problem." Switzerland's population stood at approximately 9.1 million at the end of 2025. Since 2000, it has grown by about 1.9 million people, with roughly four-fifths of that increase attributable to net international migration. Swiss federal authorities measure the increase since the introduction of free movement of persons in 2002 at around 1.7 million. Foreign nationals now make up about 27% of the resident population, while migration-background shares are higher. In 2024, 41% of Switzerland's permanent resident population aged 15 and over had a migration background, including first-generation and second-generation residents. Ermotti highlighted the scale of the demographic shift, noting that Switzerland's foreign-born share is comparable to Australia's and roughly double Germany's. The "No to a Switzerland with 10 Million" initiative, backed by the right-wing Swiss People's Party (SVP), would enshrine a hard population limit in the Federal Constitution. If passed , it would require Switzerland's permanent resident population to remain below 10 million until 2050. If the population exceeds 9.5 million before then, the Federal Council and ...